New hope for stubborn heartburn: experimental drug targets symptoms
NCT ID NCT06704100
First seen Oct 31, 2025 · Last updated May 22, 2026 · Updated 31 times
Summary
This study tests whether a drug called Fosamprenavir-Sodium Alginate (FOS-SA) can reduce heartburn and regurgitation in people whose acid reflux doesn't improve with standard proton pump inhibitors (PPIs). About 60 adults aged 18-65 will take either FOS-SA or a placebo twice daily for 8 weeks and track their symptoms. The goal is to see if this new approach offers relief for hard-to-treat GERD.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.